Hansa Biopharma AB (OTCPK:HNSBF)
$ 3.65 0 (0%) Market Cap: 246.71 Mil Enterprise Value: 285.09 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 78/100

Q3 2024 Hansa Biopharma AB Earnings Call Transcript

Oct 17, 2024 / 12:00PM GMT
Release Date Price: $2.93
Operator

Good morning and welcome to the Hansa Biopharma interim report for January to September 2024 conference call. (Operator Instructions) Please note this event is being recorded. I would now like to turn the conference over to Søren Tulstrup, President and CEO of Hansa BioPharma. Please go ahead.

Soeren Tulstrup
Hansa Biopharma AB - President, Chief Executive Officer

Thank you, Operator. Good afternoon, good morning and welcome to the Hansa Biopharma conference call to review the Q3 results for 2024. I'm Søren Tulstrup, President and CEO of Hansa Biopharma. Joining me today is Evan Ballantyne, Chief Financial Officer; and Hitto Kaufmann, chief R&D Officer.

Please turn to slide 2. Please allow me to draw your attention to the fact that we'll be making forward-looking statements during this presentation and you should therefore apply appropriate caution. Now please turn to slide 3 and an overview of today's agenda.

Today, we'll discuss the progress we made during the third quarter, 2024 and review our near term priorities. The presentation

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot